GlassScriptPhysician profile
Jacob L Meredith
NPI 1235766643
$2,453.61
in general payments reported to CMS, 2019-2025
16 companies · $1,003 in 2025
The $1,003 reported for 2025 was more than what 81% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $653 · 2024: $798 · 2025: $1,003.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,254 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,253.61 |
| Education | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $455.30 | 2023-2025 | |
| Axsome Therapeutics, INC. | $311.83 | 2023-2025 | Auvelity, Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $268.82 | 2023-2025 | Caplyta |
| Lundbeck LLC | $202.94 | 2025 | Rexulti |
| Inari Medical, INC. | $200.00 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Teva Pharmaceuticals USA, INC. | $190.76 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $189.48 | 2024-2025 | Lybalvi, Aristada |
| Otsuka America Pharmaceutical, INC. | $141.22 | 2024-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $137.35 | 2024 | Spravato |
| Neurocrine Biosciences, INC. | $127.26 | 2024-2025 | Ingrezza |
| Indivior INC. | $79.53 | 2023-2024 | Perseris |
| Bioxcel Therapeutics, INC. | $40.07 | 2023 | Igalmi |
| Idorsia Pharmaceuticals US INC | $36.53 | 2023 | Quviviq |
| Bausch Health US, LLC | $34.16 | 2024-2025 | Wellbutrin, Aplenzin |
| Tris Pharma INC | $23.56 | 2025 | Dyanavel Xr |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $14.80 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Meredith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.